OSLO – November 10, 2026 – DoMore Diagnostics, a leader in AI and deep-learning precision medicine for cancer, is pleased to announce that patents covering its Histotype Px® digital biomarkers have been granted in Australia and Singapore. Australian Patent No. 2020349037 has been granted by IP Australia, and Singapore Patent No. 11202202677R has been granted by the Intellectual Property Office of Singapore (IPOS).
The granted Australian and Singapore patents are DoMore Diagnostics' first in these territories, further extending the global IP protection of its AI-based Histotype Px® platform in the Asia-Pacific region.
Colorectal cancer is a major health burden in both countries, with close to 15,000 new cases and more than 5,000 deaths estimated in Australia in 2025. In Singapore, colorectal cancer is the second most common cancer among both men and women, with close to 13,000 new cases diagnosed between 2019 and 2023. These figures underscore the need for reliable, scalable biomarkers to guide treatment decisions in these patient populations.
Torbjørn Furuseth MD, Co-Founder and CEO at DoMore Diagnostics, commented
“Securing patents in both Australia and Singapore is an important step in building a strong, global IP position for Histotype Px. Both countries have sophisticated healthcare systems and a high unmet need in colorectal cancer, making them natural markets for our digital biomarkers as we expand access to personalized treatment decisions across the Asia-Pacific region and beyond.”
About DoMore Diagnostics
DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Our unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor. DoMore Diagnostics holds a global exclusive license to a portfolio of patents and patent applications owned by Oslo University Hospital, covering the intellectual property underpinning Histotype Px and associated machine learning methods.
DoMore Diagnostics has received funding from the European Innovation Council (EIC) Accelerator program.
About Colorectal Cancer and Histotype Px® Colorectal
Colorectal cancer is the third most common and second most deadly cancer but has seen little innovation in diagnostics and treatment in the last decades. Adjuvant chemotherapy (ACT) may be provided after primary surgery to prevent the disease from recurring, however overtreatment is prevalent with up to 85% of patients with stage II and stage III not benefiting from ACT and only suffering side effects.
Histotype Px® is an advanced deep learning algorithm that analyzes digital histology slides, separating patients into distinct Low, Intermediate and High-risk groups to guide ACT treatment decisions. Data previously published in The Lancet and The Lancet Oncology showed that the test can accurately predict survival outcomes in colorectal cancer patients. Histotype Px® Colorectal was developed to provide clinicians with valuable information to guide personalized treatment decisions and improve patient outcomes.
Histotype Px is a registered trademark in the European Union. Trademark registration status may vary by country.
For more information, please visit:
www.domorediagnostics.comLinkedInThe Lancet publication The Lancet Oncology publication
Contact:
Torbjørn Furuseth, MD torbjorn.furuseth@domorediagnostics.com